000 | 01960 a2200517 4500 | ||
---|---|---|---|
005 | 20250518070917.0 | ||
264 | 0 | _c20210106 | |
008 | 202101s 0 0 eng d | ||
022 | _a1873-7064 | ||
024 | 7 |
_a10.1016/j.neuropharm.2019.107786 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aZuo, Xialin | |
245 | 0 | 0 |
_aAttenuation of secondary damage and Aβ deposits in the ipsilateral thalamus of dMCAO rats through reduction of cathepsin B by bis(propyl)-cognitin, a multifunctional dimer. _h[electronic resource] |
260 |
_bNeuropharmacology _c01 2020 |
||
300 |
_a107786 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAmyloid beta-Peptides _xdrug effects |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntigens, CD _xmetabolism |
650 | 0 | 4 |
_aAntigens, Differentiation, Myelomonocytic _xmetabolism |
650 | 0 | 4 |
_aAntigens, Nuclear _xmetabolism |
650 | 0 | 4 |
_aCathepsin B _xantagonists & inhibitors |
650 | 0 | 4 |
_aDipeptides _xpharmacology |
650 | 0 | 4 | _aDisease Models, Animal |
650 | 0 | 4 |
_aGABA-A Receptor Antagonists _xpharmacology |
650 | 0 | 4 |
_aGlial Fibrillary Acidic Protein _xmetabolism |
650 | 0 | 4 |
_aGliosis _xmetabolism |
650 | 0 | 4 |
_aInfarction, Middle Cerebral Artery _xmetabolism |
650 | 0 | 4 |
_aNerve Tissue Proteins _xmetabolism |
650 | 0 | 4 |
_aNeuroglia _xdrug effects |
650 | 0 | 4 |
_aNeurons _xdrug effects |
650 | 0 | 4 |
_aNeuroprotective Agents _xpharmacology |
650 | 0 | 4 | _aRats |
650 | 0 | 4 |
_aTacrine _xanalogs & derivatives |
650 | 0 | 4 |
_aThalamus _xdrug effects |
650 | 0 | 4 |
_aVentral Thalamic Nuclei _xdrug effects |
700 | 1 | _aHu, Shengquan | |
700 | 1 | _aTang, Yanyan | |
700 | 1 | _aZhan, Lixuan | |
700 | 1 | _aSun, Weiwen | |
700 | 1 | _aZheng, Jianhua | |
700 | 1 | _aHan, Yifan | |
700 | 1 | _aXu, En | |
773 | 0 |
_tNeuropharmacology _gvol. 162 _gp. 107786 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.neuropharm.2019.107786 _zAvailable from publisher's website |
999 |
_c30311804 _d30311804 |